Minovia Therapeutics Company

Minovia develops personalized off-the-shelf therapeutic products for orphan mitochondrial diseases, using a proprietary method of isolating mitochondria – which produces most of the chemical energy needed to maintain normal cellular function – from placentas or from white blood cells and freezing it. They are conducting proof-of-concept trials in a disease called Pearson Syndrome, affecting only about 100 patients worldwide. Minovia’s next targets include Kearns-Sayre Syndrome, mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes and Leber hereditary optic neuropathy.
Technology: N/A
Industry: Personalized Medicine
Headquarters: Tirat Hacarmel, Israel
Founded Date: 2011
Employees Number: Undisclosed
Funding Status: N/A

Visit Website
Register and Claim Ownership